Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Total Liabilities (2016 - 2025)

Historic Total Liabilities for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $50.9 million.

  • CytomX Therapeutics' Total Liabilities fell 6868.56% to $50.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.9 million, marking a year-over-year decrease of 6868.56%. This contributed to the annual value of $121.0 million for FY2024, which is 5145.66% down from last year.
  • As of Q3 2025, CytomX Therapeutics' Total Liabilities stood at $50.9 million, which was down 6868.56% from $55.1 million recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Total Liabilities ranged from a high of $353.5 million in Q1 2021 and a low of $50.9 million during Q3 2025
  • Moreover, its 5-year median value for Total Liabilities was $294.2 million (2023), whereas its average is $246.3 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 418.29% in 2021, then plummeted by 7104.32% in 2025.
  • Quarter analysis of 5 years shows CytomX Therapeutics' Total Liabilities stood at $339.9 million in 2021, then grew by 1.99% to $346.6 million in 2022, then fell by 28.1% to $249.2 million in 2023, then tumbled by 51.46% to $121.0 million in 2024, then tumbled by 57.96% to $50.9 million in 2025.
  • Its Total Liabilities was $50.9 million in Q3 2025, compared to $55.1 million in Q2 2025 and $73.4 million in Q1 2025.